GlassScriptPhysician profile
Hector De Jesus
NPI 1063591790
$5,477.73
in general payments reported to CMS, 2019-2025
38 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $624 · 2021: $914 · 2022: $836 · 2023: $529 · 2024: $659 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,629.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $748.88 | 2021-2024 | Oasis, Stravix, Grafix |
| Glaxosmithkline, LLC. | $484.49 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $442.94 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $291.92 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $288.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $275.32 | 2020-2025 | Gardasil 9, Capvaxive |
| Novo Nordisk INC | $256.04 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $233.99 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.97 | 2020-2025 | Jardiance |
| Organogenesis INC. | $197.84 | 2022-2023 | Puraply Antimicrobial |
| Abbvie INC. | $186.68 | 2021-2025 | |
| Urgo Medical North America, LLC | $170.22 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Pfizer INC. | $152.96 | 2020-2025 | |
| Silk Road Medical, INC. | $145.38 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Koya Medical, INC. | $144.37 | 2024 | Dayspring, Koya Medical |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector De Jesus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.